Replimune Group, Inc.

Replimune Group is developing RP1 (vusolimogene oderparepvec), a genetically-engineered oncolytic virus for advanced melanoma — the Phase 3 IGNYTE trial. The stock is essentially flat YTD as the market digests the FDA resubmission acceptance and prepares for the August 2 PDUFA date.

• Revenue is zero — this is a pre-commercial biotech; the equity value depends entirely on RP1 approval and commercial launch trajectory.
• The June 26 FDA acceptance of the RP1 BLA resubmission (Class 1 resubmission) sets up the August 2 PDUFA date as the specific binary catalyst — real regulatory milestone with a dated resolution.
• The Johnson Fistel investor investigation notice (July 15) is opportunistic law-firm activity; noise rather than a specific claim signal at this stage.
• The 'AdCom landing first as more meaningful than PDUFA' framing captures the specific regulatory-process concern — briefing docs, panel framing, vote language are the specific catalysts.
• Zero insider transactions in the last 30 days at 70th percentile of 52-week range — clean absence of distributing signal ahead of the pivotal PDUFA date.

August 2 PDUFA date is the everything moment: a clean RP1 approval is where the equity re-rates dramatically; another Complete Response Letter or additional post-marketing requirements is where the tape breaks below $8. Real oncolytic-virus catalyst play with real August 2 dated regulatory event — the setup is binary and depends on the FDA decision.